BR0109549A - Utilização de moléculas que se ligam a cd25 no tratamento de doenças inflamatórias do trato gastrointestinal - Google Patents

Utilização de moléculas que se ligam a cd25 no tratamento de doenças inflamatórias do trato gastrointestinal

Info

Publication number
BR0109549A
BR0109549A BR0109549-8A BR0109549A BR0109549A BR 0109549 A BR0109549 A BR 0109549A BR 0109549 A BR0109549 A BR 0109549A BR 0109549 A BR0109549 A BR 0109549A
Authority
BR
Brazil
Prior art keywords
tyr
treatment
gastrointestinal tract
inflammatory diseases
phe
Prior art date
Application number
BR0109549-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Hansjoerg Adam
Lothar Faerber
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR0109549A publication Critical patent/BR0109549A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR0109549-8A 2000-03-30 2001-03-28 Utilização de moléculas que se ligam a cd25 no tratamento de doenças inflamatórias do trato gastrointestinal BR0109549A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0007911.1A GB0007911D0 (en) 2000-03-30 2000-03-30 Organic compounds
PCT/EP2001/003541 WO2001072845A1 (en) 2000-03-30 2001-03-28 Use of cd25 binding molecules in the treatment of inflammatory diseases of the gastro-intestinal tract

Publications (1)

Publication Number Publication Date
BR0109549A true BR0109549A (pt) 2003-06-10

Family

ID=9888901

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0109549-8A BR0109549A (pt) 2000-03-30 2001-03-28 Utilização de moléculas que se ligam a cd25 no tratamento de doenças inflamatórias do trato gastrointestinal

Country Status (18)

Country Link
US (2) US20050226872A1 (https=)
EP (1) EP1268553A1 (https=)
JP (1) JP2003528890A (https=)
KR (2) KR20080079702A (https=)
CN (1) CN1416432A (https=)
AU (2) AU4651601A (https=)
BR (1) BR0109549A (https=)
CA (1) CA2401249A1 (https=)
GB (1) GB0007911D0 (https=)
HU (1) HUP0301846A3 (https=)
IL (1) IL151089A0 (https=)
NO (1) NO20024579L (https=)
NZ (1) NZ520547A (https=)
PL (1) PL357014A1 (https=)
RU (1) RU2286797C2 (https=)
SK (1) SK13892002A3 (https=)
WO (1) WO2001072845A1 (https=)
ZA (1) ZA200207736B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2443405A1 (en) * 2001-04-06 2002-10-17 University Of Bristol Use of cd25 binding molecules in steroid-resistant patients
EP2235536A4 (en) * 2007-12-20 2011-05-04 Lab Corp America Holdings HER-2-DIAGNOSTIC PROCEDURE
ES2637411T3 (es) 2008-12-01 2017-10-13 Laboratory Corporation Of America Holdings Métodos y ensayos para medir p95 Y/O p95 en una muestra y anticuerpos específicos para p95
EP2387711B1 (en) * 2009-01-15 2015-04-22 Laboratory Corporation of America Holdings Methods of determining patient response by measurement of her-3
JP2012515353A (ja) * 2009-01-15 2012-07-05 ラボラトリー コーポレイション オブ アメリカ ホールディングス Ｈｅｒ−２発現の測定による患者の反応を判定する方法
RU2500427C2 (ru) * 2010-07-15 2013-12-10 Олег Ильич Эпштейн Лекарственное средство для лечения функциональных нарушений желудочно-кишечного тракта и способ лечения функциональных нарушений желудочно-кишечного тракта
MX367097B (es) * 2011-05-02 2019-08-05 Millennium Pharm Inc FORMULACION PARA ANTICUERPO ANTI-A4ß7.
WO2018106945A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
WO2018183929A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
EP3883635A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
CN115666704B (zh) 2019-12-13 2025-09-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT60768A (en) * 1990-03-16 1992-10-28 Sandoz Ag Process for producing cd25 fixing molecules
JPH05244982A (ja) * 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US6013256A (en) * 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation
DE69937057T2 (de) * 1998-07-27 2008-05-29 Novartis Ag Verwendung von basiliximab zur behandlung von rheumatoider arthritis und hauterkrankungen

Also Published As

Publication number Publication date
HUP0301846A2 (hu) 2003-09-29
KR20020084107A (ko) 2002-11-04
AU2001246516B2 (en) 2005-06-30
CA2401249A1 (en) 2001-10-04
NZ520547A (en) 2005-04-29
PL357014A1 (en) 2004-07-12
ZA200207736B (en) 2003-05-08
NO20024579L (no) 2002-11-11
SK13892002A3 (sk) 2003-05-02
IL151089A0 (en) 2003-04-10
CN1416432A (zh) 2003-05-07
US20050226872A1 (en) 2005-10-13
RU2002127800A (ru) 2004-03-27
US20090041775A1 (en) 2009-02-12
KR20080079702A (ko) 2008-09-01
GB0007911D0 (en) 2000-05-17
JP2003528890A (ja) 2003-09-30
RU2286797C2 (ru) 2006-11-10
WO2001072845A1 (en) 2001-10-04
NO20024579D0 (no) 2002-09-24
HUP0301846A3 (en) 2010-07-28
EP1268553A1 (en) 2003-01-02
AU4651601A (en) 2001-10-08

Similar Documents

Publication Publication Date Title
CY1110033T1 (el) Τεχνητα ανθρωπινα θεραπευτικα αντισωματα εναντια σε ισομορφες cd45
BR0207151A (pt) Moléculas de aglutinação terapêuticas
BR0112086A (pt) Anticorpos para mcp-1 humano
BRPI0513959A (pt) anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
BR0109549A (pt) Utilização de moléculas que se ligam a cd25 no tratamento de doenças inflamatórias do trato gastrointestinal
CY1120723T1 (el) Ανταγωνιστικα αντισωματα il-17
ECSP066294A (es) Un conjugado citotóxico ca6 antígeno-específico y métodos para utilizar el mismo
PE20020319A1 (es) ANTICUERPOS PARA IL-1ß HUMANA
BRPI0410338A (pt) composição farmacêutica compreendendo um constructo de anticorpo biespecìfico para epcam, processo para sua produção, uso de um constructo biespecìfico, kit contendo o mesmo e método para a prevenção, tratamento ou alìvio de uma doença tumoral
PE20160651A1 (es) Proteinas de union a il-17
EA201100694A1 (ru) Антитело к cd38 человека и его применение
ZA200702879B (en) Single domain antibodies against TNFR1 and methods of use therefor
ATE473760T1 (de) Monoklonale antikörper gegen den hepatozyten- wachstumsfaktor
ECSP088241A (es) Un conjugado citotóxico ca6 antígeno-específico y métodos para utilizar el mismo
NZ575245A (en) Targeted binding agents directed to pdgfr-alpha and uses thereof
WO2007071422A3 (en) Pharmaceutical antibody compositions with resistance to soluble cea
DE602005020474D1 (de) Antikörper gegen Phosphorylcholinkonjugate
DE60129278D1 (de) Gegen das SEMP1-Protein gerichtete Antikörper, Verfahren zu deren Herstellung, und deren Anwendungen
AU5728699A (en) Use of cd25 binding molecules in the treatment of rheumatoid arthritis or skin diseases
TH79793A (th) โมเลกุลของแอนติบอดีที่มีความจำเพาะต่อ il-17 ของมนุษย์
EP2674440A3 (en) Multivalent immunoglobulin-based bioactive assemblies
TH53886A (th) แอนติบอดี้ต่อ il-1b ในมนุษย์
TH114402A (th) แอนติบอดีของ il-17 แอนติโกนิสติก
TH71073A (th) แอนติบอดีโมเลกุลที่มีความจำเพาะสำหรับ il-1(เบตา) ของคน
TH64455A (th) สารภูมิต้านทาน mcp-1 ในมนุษย์

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUI DADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2112 DE 28/06/2011.